Eric M. Dube's most recent trade in Travere Therapeutics Inc was a trade of 45,000 Performance-based restricted stock units done . Disclosure was reported to the exchange on May 4, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2026 | 45,000 | 45,000 | - | - | Performance-based restricted stock units | |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2026 | 22,500 | 22,500 | - | - | Performance-based restricted stock units | |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2026 | 22,500 | 455,386 (1%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 43.95 per share. | 04 May 2026 | 22,500 | 432,886 (1%) | 0% | 44.0 | 988,875 | Common Stock |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Apr 2026 | 64,000 | 496,886 (1%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 41.01 per share. | 13 Apr 2026 | 56,815 | 440,071 (1%) | 0% | 41.0 | 2,329,983 | Common Stock |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 41.75 per share. | 13 Apr 2026 | 7,165 | 432,906 (1%) | 0% | 41.8 | 299,139 | Common Stock |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 42.65 per share. | 13 Apr 2026 | 20 | 432,886 (1%) | 0% | 42.7 | 853 | Common Stock |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.46 per share. | 01 Apr 2026 | 60,000 | 492,886 (1%) | 0% | 15.5 | 927,600 | Common Stock |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2026 | 60,000 | 0 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 30.55 per share. | 01 Apr 2026 | 34,902 | 457,984 (1%) | 0% | 30.5 | 1,066,256 | Common Stock |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 31.46 per share. | 01 Apr 2026 | 25,098 | 432,886 (1%) | 0% | 31.5 | 789,583 | Common Stock |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2026 | 303,600 | 303,600 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2026 | 113,800 | 532,973 (1%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 32.06 per share. | 31 Jan 2026 | 66,452 | 466,521 (1%) | 0% | 32.1 | 2,130,451 | Common Stock |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 32.70 per share. | 31 Jan 2026 | 33,635 | 432,886 (1%) | 0% | 32.7 | 1,099,865 | Common Stock |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2026 | 51,865 | 120,000 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.46 per share. | 23 Jan 2026 | 51,865 | 471,038 (1%) | 0% | 15.5 | 801,833 | Common Stock |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 30.10 per share. | 23 Jan 2026 | 51,865 | 419,173 (0%) | 0% | 30.1 | 1,560,981 | Common Stock |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.46 per share. | 23 Jan 2026 | 8,135 | 427,308 (0%) | 0% | 15.5 | 125,767 | Common Stock |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 30.01 per share. | 23 Jan 2026 | 8,135 | 419,173 (0%) | 0% | 30.0 | 244,153 | Common Stock |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2026 | 8,135 | 171,865 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.46 per share. | 28 Oct 2025 | 92,872 | 512,045 (1%) | 0% | 15.5 | 1,435,801 | Common Stock |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2025 | 92,872 | 207,128 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 30.38 per share. | 28 Oct 2025 | 92,872 | 419,173 (0%) | 0% | 30.4 | 2,821,358 | Common Stock |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2025 | 27,128 | 180,000 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 30.12 per share. | 28 Oct 2025 | 27,128 | 419,173 (0%) | 0% | 30.1 | 817,074 | Common Stock |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.46 per share. | 28 Oct 2025 | 27,128 | 446,301 (1%) | 0% | 15.5 | 419,399 | Common Stock |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2025 | 18,924 | 438,097 (1%) | 0% | - | Common Stock | |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2025 | 18,924 | 18,924 | - | - | Performance-based restricted stock units | |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 21.05 per share. | 02 May 2025 | 18,924 | 419,173 (0%) | 0% | 21.0 | 398,350 | Common Stock |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 24.04 per share. | 11 Feb 2025 | 11,375 | 419,173 (0%) | 0% | 24.0 | 273,455 | Common Stock |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 260,000 | 260,000 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 130,000 | 481,239 (1%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 20.21 per share. | 31 Jan 2025 | 50,691 | 430,548 (0%) | 0% | 20.2 | 1,024,343 | Common Stock |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 19.46 per share. | 22 Jan 2025 | 10,736 | 351,239 (0%) | 0% | 19.5 | 208,923 | Common Stock |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Sep 2024 | 32,500 | 383,100 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 11.52 per share. | 05 Sep 2024 | 21,125 | 361,975 (0%) | 0% | 11.5 | 243,360 | Common Stock |
| Travere Therapeutics Inc | Dube Eric M. | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 360,000 | 360,000 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 135,000 | 369,722 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | M. Dube Eric | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 8.86 per share. | 31 Jan 2024 | 10,016 | 350,600 (0%) | 0% | 8.9 | 88,742 | Common Stock |
| Travere Therapeutics Inc | Dube M. Eric | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 8.53 per share. | 31 Jan 2024 | 9,106 | 360,616 (0%) | 0% | 8.5 | 77,693 | Common Stock |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 8.96 per share. | 23 Jan 2024 | 7,873 | 234,722 (0%) | 0% | 9.0 | 70,542 | Common Stock |
| Reneo Pharmaceuticals Inc | Eric M. Dube | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Travere Therapeutics Inc | Eric M. Dube | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 260,000 | 260,000 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Eric M. Dube | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 97,500 | 245,346 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Eric M. Dube | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 32,500 | 32,500 | - | - | Performance-based restricted stock units | |
| Travere Therapeutics Inc | Eric M. Dube | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 22.25 per share. | 31 Jan 2023 | 8,196 | 237,150 (0%) | 0% | 22.3 | 182,361 | Common Stock |
| Travere Therapeutics Inc | Eric M. Dube | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 21.50 per share. | 24 Jan 2023 | 6,442 | 147,846 (0%) | 0% | 21.5 | 138,503 | Common Stock |
| Travere Therapeutics Inc | Eric M. Dube | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 20.75 per share. | 05 Jan 2023 | 5,625 | 154,288 (0%) | 0% | 20.8 | 116,719 | Common Stock |